MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
MIRA Pharmaceuticals announced July 6, 2026 preclinical study results for SKNY-1, an oral drug candidate for obesity and addiction. The optimized oral formulation demonstrated favorable bioavailability, robust brain penetration, substantial liver exposure, and pharmacokinetics supporting once-daily dosing. No specific dollar amounts, counterparties, or share data were disclosed; this is a preclinical milestone announcement for a company-stage program.
Why this rating
Preclinical success in lead program de-risks development path for $16M-cap company; advances toward IND/clinical stage, material for company size, but still early-stage drug candidate with significant regulatory and commercial risk ahead.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.